Still Looking For The Off-The-Shelf Breakthrough, Allogene Touts Myeloma CAR-T Candidate
Raises Hopes Of Challenging Abecma And Carvykti
Executive Summary
While a cloud hangs over the future of its CD19-targeting allogeneic candidate, Allogene points to preclinical potential of superior efficacy for ALLO-715.
You may also be interested in...
From Auto To Allo: Poseida Tries To Pick The Winning CAR-T Team
The company is winding down its autologous myeloma CAR-T program as competition in that market heats up and interest in off-the-shelf CAR-Ts grows.
Bayer Shuffles Atara’s CAR-Ts Out Of Its Cell Therapy Deck
Bayer is handing back rights to two early-stage off-the-shelf CAR-Ts to Atara, but the split could still be good news for the biotech company.
Bavarian Nordic Rises As It Meets Demand For Monkeypox Vaccine
The Danish company has the world’s only licensed monkeypox vaccine and is now fielding enquiries from concerned governments from around the world.